29 June 2026

First two cases completed in Queensland Children's Hospital clinical trial for cleft lip

Highlights

- **Osteopore is delighted to announce that the first two patients for the cleft lip augmentation clinical trial, conducted at the Queensland Children's Hospital (QCH), have successfully received their implants.**
- **As previously announced on 2 June 2026[1], Osteopore and Queensland Children's Hospital (QCH) launched and commenced a clinical trial for paranasal augmentation in 5 paediatric patients with unilateral (one-sided) cleft lip – which is the augmentation of the nose and surrounding upper jaw structure.**
- **As recently announced on 26 Jun 2026[2], all 5 patients have been recruited to the study.**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that the first two patients for the cleft lip augmentation clinical trial, conducted at the Queensland Children's Hospital (QCH), have successfully received their implants.

[1] ASX announcement, "OSX & QCH launch trial for nasoalveolar augment in children", 2 June 2026.

[2] ASX announcement, "QCH cleft lip clinical study patient recruitment completed", 26 June 2026.

As previously announced on 2 June 2026[1], QCH will conduct a single-arm feasibility trial, with the recruitment of up to 5 patients expected by end of 2026. Patient follow-up will continue for 12 months after surgery.

As a follow-up update announced on 26 Jun 2026[2], all 5 patients have now been recruited to the study.

The trial is led by Dr. Yun Phua, a Plastic and Reconstructive Surgeon based at QCH and Mater Hospital, is the second paediatric study led by Dr. Phua – the first study was for the treatment of temporal hollowing, announced on 23 May 2025[3].

Cleft lip and palate affects approximately 1 in 1,000 births globally[4], making it one of the most prevalent congenital conditions worldwide. Patients typically undergo multiple reconstructive procedures throughout childhood and adolescence.

The global cleft lip and palate repair market was valued at approximately USD 1.2b (~AUD 1.7b) in 2024 and is forecast to reach USD 1.9b (~AUD 2.7b) by 2033, growing at a CAGR of 5.5% [5]. Growth is being driven by rising surgical volumes, increasing awareness of treatment options, and the adoption of advanced biomaterials and surgical techniques.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited

Mark Leong
Executive Chairman
Osteopore Limited

[3] ASX announcement, "OSX partners QCH in trial for temporal hollowing in children", 23 May 2025.

[4] DOI: 10.15761/OHNS.1000246

[5] https://www.verifiedmarketreports.com/product/cleft-lip-and-palate-repair-market/

E: lim_yujing@osteopore.com
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.